Abstract: There is provided a system and method for automated sequence determination using pattern-directed aligned pattern clustering. The method includes: determining a set of seed patterns; generating an address table mapping the determined sets of seed patterns to occurrences of sequences of seed patterns in the protein nucleotide sequence; determining a breakpoint gap between two respective seed patterns in an occurrence of one of the sequences in the address table; for each sequence of seed patterns in the address table, where there is a breakpoint gap, merging the respective seed patterns in the sequence surrounding the breakpoint gap with the breakpoint gap into an extended seed pattern, otherwise merging the respective seed patterns in the sequence into an extended seed pattern; and determining rare mutant patterns from the extended seed patterns by comparing extended seed patterns.

Abstract: Systems and techniques that provide context-aware badge display in online communities are disclosed. Badges are identified for display based on the contexts of the online interfaces in which the badges will be displayed. When the badges awarded to a user are to be displayed in a particular online interface, the online community of that online interface is identified and used to display appropriate badges. Badges awarded to the user in the particular online community of the online interface and one or more related online communities are displayed. The related communities are identified based on a hierarchy of communities that identifies relationships between the online communities. Badges can be displayed using different display rules that can be changed over time and vary for different online communities.

Abstract: Techniques and systems are described to determine levels of competency of users as part of an online community and control generation of subsequent digital content to be used interaction of the online community with the users based on this determination. In one example, determination of the level of competency is based on relevance to topics of the online community. In another example, a determination is made as to whether the topic of the online community is stable before using user competency scores to control generation of subsequent digital content. In a further example, users of the online community are identified as exhibiting dormant or non-dormant behavior and used as a basis to control generation of subsequent digital content. In yet another example, user competency scores are adjusted based on a decay factor to address dormancy of users over a period of time.

Abstract: Techniques and systems are described to determine levels of competency of users as part of an online community and control generation of subsequent digital content to be used interaction of the online community with the users based on this determination. In one example, determination of the level of competency is based on relevance to topics of the online community. In another example, a determination is made as to whether the topic of the online community is stable before using user competency scores to control generation of subsequent digital content. In a further example, users of the online community are identified as exhibiting dormant or non-dormant behavior and used as a basis to control generation of subsequent digital content. In yet another example, user competency scores are adjusted based on a decay factor to address dormancy of users over a period of time.

Abstract: Techniques and systems are described to determine levels of competency of users as part of an online community and control generation of subsequent digital content to be used interaction of the online community with the users based on this determination. In one example, determination of the level of competency is based on relevance to topics of the online community. In another example, a determination is made as to whether the topic of the online community is stable before using user competency scores to control generation of subsequent digital content. In a further example, users of the online community are identified as exhibiting dormant or non-dormant behavior and used as a basis to control generation of subsequent digital content. In yet another example, user competency scores are adjusted based on a decay factor to address dormancy of users over a period of time.

Abstract: Techniques and systems are described to determine levels of competency of users as part of an online community and control generation of subsequent digital content to be used interaction of the online community with the users based on this determination. In one example, determination of the level of competency is based on relevance to topics of the online community. In another example, a determination is made as to whether the topic of the online community is stable before using user competency scores to control generation of subsequent digital content. In a further example, users of the online community are identified as exhibiting dormant or non-dormant behavior and used as a basis to control generation of subsequent digital content. In yet another example, user competency scores are adjusted based on a decay factor to address dormancy of users over a period of time.

Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Abstract: The present invention relates to compounds which modulate interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) and are useful in the prevention or treatment of inflammatory, cell proliferative and immune-related conditions and diseases. Specifically, provided herein are inhibitors of IRAK4 of Formula I and pharmaceutical compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? combinations thereof.

Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof.

Abstract: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-? combinations thereof.

Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Abstract: The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R1, R3, Z, L1, and L2 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.